Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
8.270
+0.260 (+3.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Today 18:00 EST
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
An Investor's Guide to the Artificial Intelligence (AI) Value Chain
Today 7:15 EST
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
November 28, 2024
Via
Benzinga
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
November 07, 2024
Via
Benzinga
Peering Into Recursion Pharmaceuticals's Recent Short Interest
November 04, 2024
Via
Benzinga
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
October 30, 2024
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
December 06, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 04, 2024
Via
Benzinga
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
December 04, 2024
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios.
December 04, 2024
Via
The Motley Fool
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
December 03, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
December 02, 2024
Via
Benzinga
NVIDIA Invested in These 2 AI Stocks, Should You?
December 02, 2024
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
November 27, 2024
Jim Cramer praises Reddit, Inc. but warns of auto parts made in China. Recursion Pharmaceuticals and Dow Inc. face challenges. Super Micro Computer sells due to accounting irregularities.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
November 26, 2024
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Innovative Stocks That Could Deliver Outsize Returns
November 22, 2024
Via
The Motley Fool
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
November 20, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
November 15, 2024
Nvidia's purchase of 7.72 million shares of Applied Digital boosted the company's revenue and earnings. Applied Digital plans to expand its data centers and AI cloud infrastructure.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
November 15, 2024
Nvidia has disclosed an investment in Applied Digital, a digital infrastructure provider. Nvidia stock dipped while APLD stock rose.
Via
Investor's Business Daily
Recursion and Exscientia Shareholders Approve the Proposed Combination
November 13, 2024
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
November 12, 2024
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
November 11, 2024
Via
Benzinga
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
10 Health Care Stocks Moving In Monday's Pre-Market Session
November 04, 2024
Via
Benzinga
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
November 02, 2024
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
Via
The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
October 26, 2024
This company stands to benefit from a shifting pharmaceutical industry landscape.
Via
The Motley Fool
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
October 22, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Prediction: These 2 Stocks Could Soar in 2025
October 17, 2024
The key word here is "could."
Via
The Motley Fool
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
October 15, 2024
Wood has a stake in this stock, but it's hardly an "all-in" bet.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.